News | Jacobio Pharma

95 press releases in total

2026

Jul 21, 2026

Jacobio's BET Inhibitor JAB-8263 for Myelofibrosis Included in CDE Rare Disease Innovative Drug Development Pilot Program

[More]
Jul 20, 2026

Jacobio Announces First Patient Dosed in China in Phase Ib/III Trial of JAB-23E73 in Combination with Chemotherapy for First-Line Treatment of KRAS-Mutant Pancreatic Cancer

[More]
Jul 10, 2026

Jacobio Pharma’s Associate Company Jacoray Receives IND Clearance in China for JAR-2203 Injection

[More]
Jul 6, 2026

Jacobio Investee GenEditBio Receives NMPA IND Clearance for Lead Genome-Editing Program

[More]
Jun 25, 2026

Jacobio’s Invested Company HebeCell Received FDA IND Clearance for Its Cell Therapy Program

[More]
Jun 18, 2026

Jacobio Pharma Engages Pharmaron to Initiate Manufacturing of JAB-23E73 for Registrational Clinical Trials

[More]
May 15, 2026

Jacobio Pharma’s BET Inhibitor JAB-8263 Approved for Phase IIa Clinical Trial in Rheumatoid Arthritis in China

[More]
May 13, 2026

Jacobio Pharma Appoints Dr. Yan Chen as Vice President of CMC to Accelerate Development of Its Small Molecule and xADC Platforms

[More]
May 11, 2026

Jacobio-Licensed KRAS G12C and SHP2 Inhibitor Combination Receives Breakthrough Therapy Designation in China

[More]
Mar 30, 2026

Jacobio Pharma Receives US$100 Million Upfront Payment from AstraZeneca

[More]
Mar 11, 2026

Jacobio Announces 2025 Annual Results

[More]

2025

Dec 21, 2025

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

[More]
Dec 5, 2025

Glecirasib Colorectal Cancer Data Published in The Lancet Gastroenterology & Hepatology

[More]
Dec 1, 2025

Jacobio’s KRAS G12C and SHP2 Combination Therapy Published in The Lancet Respiratory Medicine

[More]
Nov 13, 2025

Jacobio Pharma Announces Establishment of Co-CEO System

[More]
Nov 11, 2025

Jacobio Included in the MSCI China All Shares Small Cap Index

[More]
Oct 24, 2025

Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference

[More]
Oct 15, 2025

Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline

[More]
Aug 30, 2025

Jacobio Pharma Announces 2025 Interim Results

[More]
Jul 2, 2025

Jacobio Pharma Completes First Patient Dosage of Pan-KRAS Inhibitor in U.S.

[More]

Pages